| Diabetes Mellitus, Non-Insulin-Dependent

Mounjaro vs Januvia

Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.

Deep comparison between: Mounjaro vs Januvia with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsJanuvia has a higher rate of injection site reactions vs Mounjaro based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Januvia but not Mounjaro, including UnitedHealthcare

Category

Mounjaro

Januvia

At A Glance

RouteSC injection

FrequencyOnce weekly

ClassGIP/GLP-1 receptor agonist

RouteOral

FrequencyOnce daily

ClassDPP-4 inhibitor

Indications

Diabetes Mellitus, Non-Insulin-Dependent

Diabetes Mellitus, Non-Insulin-Dependent

Dosing

Diabetes Mellitus, Non-Insulin-Dependent Start at 2.5 mg SC once weekly; increase to 5 mg after 4 weeks; escalate in 2.5 mg increments every >=4 weeks as needed; max 15 mg once weekly in adults and 10 mg once weekly in pediatric patients 10 years of age and older.

Diabetes Mellitus, Non-Insulin-Dependent 100 mg orally once daily, with or without food.

Renal impairment (eGFR 30 to <45 mL/min/1.73 m2) 50 mg once daily.

Severe renal impairment or ESRD (eGFR <30 mL/min/1.73 m2) 25 mg once daily; may be administered without regard to the timing of dialysis.

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Known serious hypersensitivity to tirzepatide or any excipient in MOUNJARO

History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema

Drug Interactions

299View drug interactions

1250View drug interactions

Adverse Reactions

Most common (>=5%) Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain

Serious Risk of thyroid C-cell tumors, acute pancreatitis, hypoglycemia (with insulin secretagogues or insulin), hypersensitivity reactions, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, diabetic retinopathy complications, acute gallbladder disease, pulmonary aspiration

Postmarketing Anaphylaxis, angioedema, acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation including fecal impaction, pulmonary aspiration, acute renal failure or worsening of chronic renal failure, alopecia

Most common (>=5%) Nasopharyngitis, upper respiratory tract infection, headache.

Serious Pancreatitis, heart failure, acute renal failure, hypoglycemia (with sulfonylurea or insulin), hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid.

Postmarketing Anaphylaxis, angioedema, rash, urticaria, cutaneous vasculitis, Stevens-Johnson syndrome, hepatic enzyme elevations, acute pancreatitis, worsening renal function, acute renal failure, tubulointerstitial nephritis, severe arthralgia, bullous pemphigoid, constipation, vomiting, myalgia, pain in extremity, back pain, pruritus, mouth ulceration, stomatitis, rhabdomyolysis.

Pharmacology

Tirzepatide is a dual GIP and GLP-1 receptor agonist that selectively binds and activates both receptors, enhancing first- and second-phase insulin secretion and reducing glucagon levels in a glucose-dependent manner, thereby lowering fasting and postprandial glucose, decreasing food intake, and reducing body weight.

Sitagliptin is a DPP-4 inhibitor that slows inactivation of incretin hormones (GLP-1 and GIP), increasing insulin release and decreasing glucagon levels in a glucose-dependent manner; it is selective for DPP-4 and does not inhibit DPP-8 or DPP-9 activity at therapeutic concentrations.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Mounjaro